October 13, 2015 –
DelMar Pharmaceuticals Launches Digital Corporate Communication Channels
VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2015 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that it has launched a suite of online corporate communication channels to maintain ongoing and direct communication with shareholders and other interested parties. The Company hosts official digital portals on social medial channels including Twitter, LinkedIn, Facebook, Google+ and The Chairman’s Blog.
DelMar Pharmaceuticals Logo
“We are committed to continued excellence in providing timely, clear and transparent communication,” stated Jeffrey Bacha, DelMar’s president and CEO. “We plan to utilize our social media channels, along with traditional press releases and required regulatory filings to quickly and efficiently update our shareholders, the investment community and other key stakeholders with the latest information on DelMar and the clinical progress of our first-in-class chemotherapeutic drug candidate VAL-083.”
The Chairman’s Blog is an online communication portal where the DelMar management team and oncology thought leaders can address important topics related to VAL-083 (dianhydrogalactitol) and its therapeutic potential in glioblastoma multiforme, non-small cell lung cancer, ovarian cancer and other solid tumors. The blog will also provide an opportunity to discuss advancements in key cancer treatment areas, as well corporate and industry events.
Links to the new DelMar communication tools are as follow:
The Chairman’s Blog: www.thechairmansblog.com/delmar-pharmaceuticals/
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. For more information please visit www.thechairmansblog.com.
VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.
DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar® (temozolomide).
The trial is being conducted in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA) at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO). Further details can be found at www.delmarpharma.com/clinical-trial.html.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For further information, please visit here
Contact DelMar Pharmaceuticals Investor Relations: firstname.lastname@example.org
Phone: (604) 629-5989
Twitter, LinkedIn, Facebook, and Google+
Investor Relations Counsel: Amato & Partners LLC.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
To view the original version on PR Newswire, please visit: